Search

Your search keyword '"Houbiers, Ghislain"' showing total 32 results
Start Over Author "Houbiers, Ghislain"
32 results on '"Houbiers, Ghislain"'

1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

2. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Deleporte, Amélie, Van den Eynde, Marc, Forget, Frédéric, Holbrechts, Stéphane, Delaunoit, Thierry, Houbiers, Ghislain, Kalantari, Hassan R, Laurent, Stéphanie, Vanderstraeten, Erik, De Man, Marc, Vergauwe, Philippe, Clausse, Marylene, Van Der Auwera, Jacques, D'Hondt, Lionel, Pierre, Pascal, Ghillemijn, Bjorn, Covas, Angelique, Paesmans, Marianne, Ameye, Lieveke, Awada, Ahmad, Sclafani, Francesco, Hendlisz, Alain, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Deleporte, Amélie, Van den Eynde, Marc, Forget, Frédéric, Holbrechts, Stéphane, Delaunoit, Thierry, Houbiers, Ghislain, Kalantari, Hassan R, Laurent, Stéphanie, Vanderstraeten, Erik, De Man, Marc, Vergauwe, Philippe, Clausse, Marylene, Van Der Auwera, Jacques, D'Hondt, Lionel, Pierre, Pascal, Ghillemijn, Bjorn, Covas, Angelique, Paesmans, Marianne, Ameye, Lieveke, Awada, Ahmad, Sclafani, Francesco, and Hendlisz, Alain

Abstract

While docetaxel/cisplatin/5-fluorouracil (DCF) outperforms CF in first-line gastric adenocarcinoma, toxicity remains an issue. This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/m , C 35 mg/m², F 1800 mg/m² over 24 h, on days 1 and 8 every 3 weeks, arm (1) or fortnightly DCF (D 50 mg/m , C 50 mg/m², F 2000 mg/m² over 48 h every 2 weeks, arm (2). Prophylactic granulocyte colony-stimulating factor (G-CSF) was not allowed. The primary endpoint was the rate of febrile neutropenia within the first six treatment weeks (early FN). A total of 106 eligible patients were recruited. The early and overall FN rates were 9.5% and 17% in arm 1, respectively, and 5.9% and 8% in arm 2, respectively. Grade ≥3 toxicities occurred in 81% of patients in arm 1 and 90% of patients in arm 2, the most common being neutropenia (33% vs. 61%), fatigue (27% vs. 25%), vomiting (21% vs. 12%), anorexia (19% vs. 18%), and diarrhea (17% vs. 10%). Median progression-free survival and overall survival were 5.1 (95% CI, 3.2-6.5) and 8.2 months (95% CI, 6.0-14.5), respectively, in arm 1 and 5.2 (95% CI, 3.0-6.9) and 11.9 months (95% CI, 7.4-15.9), respectively, in arm 2. Fractionated weekly and fortnightly DCF regimens are associated with a low risk of early FN, and a better hematological toxicity profile as compared to historical DCF without compromising efficacy. Both regimens offer greater convenience removing the need for systematic use of prophylactic G-CSF.

Published
2021

3. Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study

Author

Deleporte, Amélie, primary, Van den Eynde, Marc, additional, Forget, Frédéric, additional, Holbrechts, Stéphane, additional, Delaunoit, Thierry, additional, Houbiers, Ghislain, additional, Kalantari, Hassan R., additional, Laurent, Stéphanie, additional, Vanderstraeten, Erik, additional, De Man, Marc, additional, Vergauwe, Philippe, additional, Clausse, Marylene, additional, Van Der Auwera, Jacques, additional, D’Hondt, Lionel, additional, Pierre, Pascal, additional, Ghillemijn, Bjorn, additional, Covas, Angelique, additional, Paesmans, Marianne, additional, Ameye, Lieveke, additional, Awada, Ahmad, additional, Sclafani, Francesco, additional, and Hendlisz, Alain, additional

Published
2021
Full Text
View/download PDF

4. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Marc, Marechal, Raphäel, Delaunoit, Thierry, Goemine, Jean-Charles, Laurent, Stéphanie, Holbrechts, Stéphane, Paesmans, Marianne, Van Laethem, Jean-Luc, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Marc, Marechal, Raphäel, Delaunoit, Thierry, Goemine, Jean-Charles, Laurent, Stéphanie, Holbrechts, Stéphane, Paesmans, Marianne, and Van Laethem, Jean-Luc

Abstract

BACKGROUND: There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies. PATIENTS AND METHODS: REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase II study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic biliary tract cancer that progressed after gemcitabine/platinum chemotherapy. Patients were randomly assigned 1 : 1 to best supportive care plus either regorafenib 160 mg once daily 3 weeks on/1 week off or placebo until progression or unacceptable toxicity. No crossover was allowed. The primary objective was progression-free survival (PFS). Secondary objectives were response rate, overall survival, and translational analysis. RESULTS: Sixty-six patients with intrahepatic (n = 42), perihilar (n = 6), or extrahepatic (n = 9) cholangiocarcinoma, or gallbladder carcinoma (n = 9) were randomized, 33 to each treatment group (33 per group). At a median follow-up of 24 months, all patients had progressed and six patients were alive. Median treatment duration was 11.0 weeks [95% confidence interval (CI): 6.0-15.9] in the regorafenib group and 6.3 weeks (95% CI: 3.9-7.0) in the placebo group (P = 0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95% CI: 59-90) in the regorafenib group and 34% with placebo (95% CI: 18-51; P = 0.002). Median PFS in the regorafenib group was 3.0 months (95% CI: 2.3-4.9) and 1.5 months (95% CI: 1.2-2.0) in the placebo group (hazard ratio 0.49; 95% CI: 0.29-0.81; P = 0.004) and median overall survival was 5.3 months (95% CI: 2.7-10.5) and 5.1 months (95% CI: 3.0-6.4), respectively (P = 0.28). There were no unexpected/new safety signals. CONCLUSION: Regorafenib significantly improved PFS and tumor control in patients wi

Published
2020

5. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial

Author

Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goemine, J.C., Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, Van Laethem, Jean-Luc, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goemine, J.C., Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, and Van Laethem, Jean-Luc

Abstract

Background: There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies. Patients and methods: REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase II study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic biliary tract cancer that progressed after gemcitabine/platinum chemotherapy. Patients were randomly assigned 1: 1 to best supportive care plus either regorafenib 160 mg once daily 3 weeks on/1 week off or placebo until progression or unacceptable toxicity. No crossover was allowed. The primary objective was progression-free survival (PFS). Secondary objectives were response rate, overall survival, and translational analysis. Results: Sixty-six patients with intrahepatic (n = 42), perihilar (n = 6), or extrahepatic (n = 9) cholangiocarcinoma, or gallbladder carcinoma (n = 9) were randomized, 33 to each treatment group (33 per group). At a median follow-up of 24 months, all patients had progressed and six patients were alive. Median treatment duration was 11.0 weeks [95% confidence interval (CI): 6.0–15.9] in the regorafenib group and 6.3 weeks (95% CI: 3.9–7.0) in the placebo group (P = 0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95% CI: 59–90) in the regorafenib group and 34% with placebo (95% CI: 18–51; P = 0.002). Median PFS in the regorafenib group was 3.0 months (95% CI: 2.3–4.9) and 1.5 months (95% CI: 1.2–2.0) in the placebo group (hazard ratio 0.49; 95% CI: 0.29–0.81; P = 0.004) and median overall survival was 5.3 months (95% CI: 2.7–10.5) and 5.1 months (95% CI: 3.0–6.4), respectively (P = 0.28). There were no unexpected/new safety signals. Conclusion: Regorafenib significantly improved PFS and tumor control in patients wit, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2020

6. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Demols, Anne, Borbath, Ivan, Van den Eynde, Marc, Houbiers, Ghislain, Peeters, Marc, Maréchal, Raphael, Delaunoit, Thierry, Goeminne, Jean Charles., Laurent, Stéphanie, Holbrechts, Stephane, Paesmans, Marianne, Van Laethem, Jean L., ASCO-GI : American society of clinical oncology - Gastrointestinal Cancers Symposium, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Demols, Anne, Borbath, Ivan, Van den Eynde, Marc, Houbiers, Ghislain, Peeters, Marc, Maréchal, Raphael, Delaunoit, Thierry, Goeminne, Jean Charles., Laurent, Stéphanie, Holbrechts, Stephane, Paesmans, Marianne, Van Laethem, Jean L., and ASCO-GI : American society of clinical oncology - Gastrointestinal Cancers Symposium

Published
2019

7. Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors

Author

Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goeminne, Jean Charles, Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, Van Laethem, Jean-Luc, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goeminne, Jean Charles, Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, and Van Laethem, Jean-Luc

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

8. Les tumeurs kystiques du pancréas : aspects pratiques de la prise en charge.

Author

Deliège, Mégane, Houbiers, Ghislain, Blétard, Noella, Materne, Roland, Courtois, Audrey, and Focan, Christian

Abstract

Résumé: La prise en charge des tumeurs kystiques du pancréas n'est pas simple. Elles comprennent de nombreuses entités (les kystes mucineux, les kystes séreux, les tumeurs pseudo-papillaires solides (TPPS) ou les tumeurs neuroendocrines (TNE))... au pronostic variable. L'établissement de la nature du kyste est la première étape d'une bonne prise en charge, elle se base sur différentes techniques (IRM, écho-endoscopie avec ou sans cytoponction) qui peuvent être complémentaires. Un diagnostic de certitude ne peut pas toujours être établi, mais de nouvelles techniques prometteuses sont en cours de développement (microscopie confocale, étude moléculaire, etc.). En fonction de la nature de la lésion, une prise en charge chirurgicale est proposée d'emblée pour les tumeurs pseudo-papillaires solides ou un arrêt de la surveillance pour les lésions sans potentiel malin telles les cystadénomes séreux. Notons que les patients non éligibles à la chirurgie ne requièrent pas de suivi quelle que soit la nature du kyste. Pour les autres types de lésions, il existe une seconde étape dans la prise en charge qui consiste à établir la présence ou non de facteurs de mauvais pronostic. Ceux-ci ont été revus récemment par le consensus européen et orientent le patient vers une surveillance ou une prise en charge chirurgicale. The management of pancreatic cystic neoplasm is challenging. They are constituted by various entities (mucinous cyst, serous cyst, solid pseudopapillary neoplasm or cystic neuroendocrine tumour, etc.) with different and variable prognosis. The first step in management will try to determine the exact nature of the cyst. MRI and echo-endoscopy (with or without cyto-puncture) are basic technics to this establishment. Definitive diagnosis cannot always be established. Confocal microscopy or molecular analyses are new interesting tools in active development. Surgery will be systematically proposed for solid pseudopapillary tumour. In the other hand, monitoring can be stopped for harmless cysts like serous cystsadenoma. Let us point out that patients non-eligible for surgery do not require any follow up independently of cyst nature. For other types of lesion, the second step in management will be to evaluate the presence of worrying prognostic factors and further propose either an active surveillance or an appropriate surgery. The actualized European consensus in the matter will help the choice of physicians for decisions in multidisciplinary meetings. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

10. An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors.

Author

Demols, Anne, primary, Borbath, Ivan, additional, Van Den Eynde, Marc, additional, Houbiers, Ghislain, additional, Peeters, Marc, additional, Maréchal, Raphaël, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles., additional, Laurent, Stéphanie, additional, Holbrechts, Stephane, additional, Paesmans, Marianne, additional, and Van Laethem, Jean-Luc, additional

Published
2019
Full Text
View/download PDF

11. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.

Author

Demols, Anne, primary, Borbath, Ivan, additional, Van Den Eynde, Marc, additional, Houbiers, Ghislain, additional, Peeters, Marc, additional, Maréchal, Raphael, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles., additional, Laurent, Stéphanie, additional, Holbrechts, Stephane, additional, Paesmans, Marianne, additional, and Van Laethem, Jean L., additional

Published
2019
Full Text
View/download PDF

12. Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)

Author

Chiritescu, Gabriela, Dumon, Kristien, Verslype, Chris, Prenen, Hans, Houbiers, Ghislain, Peeters, Michel, Janssens, Jos, Van Daele, Daniel, Laurent, Stéphanie, Arts, Joris, Hendrickx, Koen, Borbath, Ivan, Ferrante, Michel, Bastin, F.M., Goeminne, Jean Charles, Van Laethem, Jean-Luc, Vanderstraeten, Erik, Decaestecker, Jochen, Van Vaerenbergh, Willem, Delhougne, Bernard, Van Cutsem, Eric, Chiritescu, Gabriela, Dumon, Kristien, Verslype, Chris, Prenen, Hans, Houbiers, Ghislain, Peeters, Michel, Janssens, Jos, Van Daele, Daniel, Laurent, Stéphanie, Arts, Joris, Hendrickx, Koen, Borbath, Ivan, Ferrante, Michel, Bastin, F.M., Goeminne, Jean Charles, Van Laethem, Jean-Luc, Vanderstraeten, Erik, Decaestecker, Jochen, Van Vaerenbergh, Willem, Delhougne, Bernard, and Van Cutsem, Eric

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

13. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Emile, Jean-François, primary, Julié, Catherine, additional, Le Malicot, Karine, additional, Lepage, Come, additional, Tabernero, Josep, additional, Mini, Enrico, additional, Folprecht, Gunnar, additional, Van Laethem, Jean-Luc, additional, Dimet, Stéphanie, additional, Boulagnon-Rombi, Camille, additional, Allard, Marc-Antoine, additional, Penault-Llorca, Frédérique, additional, Bennouna, Jaafar, additional, Laurent-Puig, Pierre, additional, Taieb, Julien, additional, Thaler, Josef, additional, Greil, Richard, additional, Gaenzer, Johannes, additional, Eisterer, Wolfgang, additional, Tschmelitsch, Joerg, additional, Keil, Felix, additional, Samonigg, Hellmut, additional, Zabernigg, August, additional, Schmid, Franz, additional, Steger, Günther, additional, Steinacher, Robert, additional, Andel, Johannes, additional, Jagdt, Björn, additional, Lang, Alois, additional, Fridrik, Michael, additional, Függer, Reinhold, additional, Hofbauer, Friedrich, additional, Woell, Ewald, additional, Geissler, Dietmar, additional, Lenauer, Alfred, additional, Prager, Manfred, additional, D'Haens, Geert, additional, Demolin, Gauthier, additional, Kerger, Joseph, additional, Deboever, Guido, additional, Ghillebert, Gilbert, additional, Polus, Marc, additional, Van Cutsem, Eric, additional, Kalantari, Hassan Rezaie, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles, additional, Peeters, Marc, additional, Vergauwe, Philippe, additional, Houbiers, Ghislain, additional, Humblet, Yves, additional, Janssens, Jos, additional, Schrijvers, Dirk, additional, Vanderstraeten, Erik, additional, Vermorken, Jan, additional, Van Daele, Daniel, additional, Ferrante, Michel, additional, Forget, Frederic, additional, Hendlisz, Alain, additional, Yilmaz, Mette, additional, Nielsen, Svend Erik, additional, Vestermark, Lene, additional, Larsen, Jim, additional, Zawadi, Mohamed-Ayman, additional, Bouche, Olivier, additional, Mineur, Laurent, additional, Bennouna-Louridi, Jaafar, additional, Dourthe, Louis Marie, additional, Ychou, Marc, additional, Boucher, Eveline, additional, Pezet, Denis, additional, Desseigne, Francoise, additional, Ducreux, Michel, additional, Texereau, Patrick, additional, Miglianico, Laurent, additional, Rougier, Philippe, additional, Fratte, Serge, additional, Levache, Charles-Briac, additional, Merrouche, Yacine, additional, Ellis, Stephen, additional, Locher, Christophe, additional, Ramee, Jean-Francois, additional, Garnier, Claire, additional, Viret, Frederic, additional, Chauffert, Bruno, additional, Cojean-Zelek, Isabelle, additional, Michel, Pierre, additional, Lecaille, Cedric, additional, Borel, Christian, additional, Seitz, Jean-Francois, additional, Smith, Denis, additional, Lombard-Bohas, Catherine, additional, Andre, Thierry, additional, Gornet, Jean-Marc, additional, Fein, Francine, additional, Coulon-Sfairi, Marie-Aude, additional, Kaminsky, Marie-Christine, additional, Lagasse, Jean-Paul, additional, Luet, Dominique, additional, Etienne, Pierre-Luc, additional, Gasmi, Mohamed, additional, Vanoli, Andre, additional, Nguyen, Suzanne, additional, Aparicio, Thomas, additional, Perrier, Hervé, additional, Stremsdoerfer, Noel, additional, Laplaige, Philippe, additional, Arsene, Dominique, additional, Auby, Dominique, additional, Bedenne, Laurent, additional, Coriat, Romain, additional, Denis, Bernard, additional, Geoffroy, Patrick, additional, Piot, Gilles, additional, Becouarn, Yves, additional, Bordes, Gilbert, additional, Deplanque, Gael, additional, Dupuis, Olivier, additional, Fruge, Frederic, additional, Guimbaud, Rosine, additional, Lecomte, Thierry, additional, Lledo, Gérard, additional, Sobhani, Iradej, additional, Asnacios, Amani, additional, Azzedine, Ahmed, additional, Desauw, Christophe, additional, Galais, Marie-Pierre, additional, Gargot, Dany, additional, Lam, You-Heng, additional, Abakar-Mahamat, Abakar, additional, Berdah, Jean-Francois, additional, Catteau, Sylviane, additional, Clavero-Fabri, Marie-Christine, additional, Codoul, Jean-Francois, additional, Legoux, Jean-Louis, additional, Goldfain, Denis, additional, Guichard, Pierre, additional, Verge, Denis Pere, additional, Provencal, Jocelyne, additional, Vedrenne, Bruno, additional, Brezault-Bonnet, Catherine, additional, Cleau, Denis, additional, Desir, Jean-Paul, additional, Fallik, David, additional, Garcia, Bruno, additional, Gaspard, Marie-Hélène, additional, Genet, Dominique, additional, Hartwig, Johannes, additional, Krummel, Yves, additional, Budnik, Tamara Matysiak, additional, Palascak-Juif, Vanessa, additional, Randrianarivelo, Harizo, additional, Rinaldi, Yves, additional, Aleba, Albert, additional, Darut-Jouve, Ariane, additional, de Gramont, Aimery, additional, Hamon, Herve, additional, Wendehenne, Frederic, additional, Matzdorff, Axel, additional, Stahl, Michael Konrad, additional, Schepp, Wolfgang, additional, Burk, Martin, additional, Mueller, Lothar, additional, Geissler, Michael, additional, Mantovani-Loeffler, Luisa, additional, Hoehler, Thomas, additional, Asperger, Walter, additional, Kroening, Hendrik, additional, von Weikersthal, Ludwig Fischer, additional, Fuxius, Stefan, additional, Groschek, Matthias, additional, Meiler, Johannes, additional, Trarbach, Tanja, additional, Rauh, Jacqueline, additional, Ziegenhagen, Nicolas, additional, Kretzschmar, Albrecht, additional, Graeven, Ullrich, additional, Nusch, Arnd, additional, von Wichert, Goetz, additional, Hofheinz, Ralf-Dieter, additional, Kleber, Gerhard, additional, Schmidt, Karl-Heinz, additional, Vehling-Kaiser, Ursula, additional, Baum, Claudia, additional, Schuette, Jochen, additional, Haag, Georg Martin, additional, Holtkamp, Wilhelm, additional, Potenberg, Jochen, additional, Reiber, Tobias, additional, Schliesser, Georg, additional, Schmoll, Hans-Joachim, additional, Schneider-Kappus, Wolfgang, additional, Abenhardt, Wolfgang, additional, Denzlinger, Claudio, additional, Henning, Jan, additional, Marxsen, Bartscht, additional, Derigs, Hans Guenter, additional, Lambertz, Helmut, additional, Becker-Boost, Ingulf, additional, Caca, Karel, additional, Constantin, Christian, additional, Decker, Thomas, additional, Eschenburg, Henning, additional, Gabius, Sigrun, additional, Hebart, Holger, additional, Hoffmeister, Albrecht, additional, Horst, Heinz-August, additional, Kremers, Stephan, additional, Leithaeuser, Malte, additional, Mueller, Sebastian, additional, Wagner, Siegfried, additional, Daum, Severin, additional, Schlegel, Frank, additional, Stauch, Martina, additional, Heinemann, Volker, additional, Maiello, Evaristo, additional, Latini, Luciano, additional, Zaniboni, Alberto, additional, Amadori, Dino, additional, Aprile, Giuseppe, additional, Barni, Sandro, additional, Mattioli, Rodolfo, additional, Martoni, Andrea, additional, Passalacqua, Rodolfo, additional, Nicolini, Mario, additional, Pasquini, Enzo, additional, Rabbi, Carla, additional, Aitini, Enrico, additional, Ravaioli, Alberto, additional, Barone, Carlo, additional, Biasco, Guido, additional, Tamberi, Stefano, additional, Gambi, Angelo, additional, Verusio, Claudio, additional, Marzola, Marina, additional, Lelli, Giorgio, additional, Boni, Corrado, additional, Cascinu, Stefano, additional, Bidoli, Paolo, additional, Vaghi, Massimo, additional, Cruciani, Giorgio, additional, Di Costanzo, Francesco, additional, Sobrero, Alberto, additional, Petrioli, Roberto, additional, Aglietta, Massimo, additional, Alabiso, Oscar, additional, Capuzzo, Federico, additional, Falcone, Alfredo, additional, Corsi, Domenico Cristi, additional, Labianca, Roberto, additional, Salvagni, Stefania, additional, Chiara, Silvana, additional, Ciuffreda, Libero, additional, Ferraù, Francesco, additional, Giuliani, Francesco, additional, Lonardi, Sara, additional, Gebbia, Nicola, additional, Mantovani, Giovanni, additional, Sanches, Evaristo, additional, Mellidez, Juan Carlos, additional, Santos, Pedro, additional, Freire, Joao, additional, Sarmento, Cristina, additional, Costa, Luis, additional, Pinto, Antonio Moreira, additional, Barroso, Sergio, additional, Santo, Jorge Espirito, additional, Guedes, Fátima, additional, Monteiro, Amélia, additional, Sa, Anabela, additional, Furtado, Irene, additional, Salazar, Ramon, additional, Aguilar, Enrique Aranda, additional, Herrero, Fernando Rivera, additional, Valera, Javier Sastre, additional, Ayerbes, Manuel Valladares, additional, Batlle, Jaime Feliu, additional, Gil, Silvia, additional, Esteve, Albert Abad, additional, Garcia-Giron, Carlos, additional, Vivanco, Guillermo Lopez, additional, Salvia, Antonia Salud, additional, Orduña, Vicente Alonso, additional, Garcia, Ruth Vera, additional, Gallego, Javier, additional, Sureda, Bartomeu Massuti, additional, Remon, Jordi, additional, Safont Aguilera, Maria Jose, additional, Nogueras, Luis Cirera, additional, Merino, Bernado Queralt, additional, Castro, Cristina Gravalos, additional, de Prado, Purificacion Martinez, additional, Pericay, Carlos Pijaume, additional, Figueiras, Manuel Constenla, additional, Jordan, Inmaculada Guasch, additional, Gome Reina, Maria Jose, additional, Garcia, Amelia Lopez-Ladron, additional, Garcia-Ramos, Antonio Arrivi, additional, Cervantes, Andres, additional, Martos, Carlos Fernandez, additional, Gaspar, Eugenio Marcuello, additional, Montero, Ines Cabezas, additional, Emperador, Pilar Escudero, additional, Carbonero, Ana Leon, additional, Castillo, Manuel Gallen, additional, Garcia, Teresa Garcia, additional, Lopez, Jose Garcia, additional, Flores, Encarnacion Gonzalez, additional, Morales, Monica Guillot, additional, Muñoz, Marta Llanos, additional, Martín, Ana López, additional, Maurel, Joan, additional, Camara, Juan Carlos, additional, Garcia, Rosario Dueñas, additional, Salgado, Mercedes, additional, Busquier, Isabel Hernandez, additional, Ruiz, Teresa Checa, additional, Muñoa, Adelaida Lacasta, additional, Aliguer, Miquel Nogue, additional, de Taranco, Amalia Velasco Ortiz, additional, Ureña, Miguel Mendez, additional, Gaspa, Ferran Losa, additional, Ponce, Jose Juan, additional, Roig, Carlos Bosch, additional, Jimenez, Pedro Valero, additional, Brotons, Antonio Galan, additional, Rodriguez, Santiago Albiol, additional, Martinez, Jose Ales, additional, Ruiz, Liliana Canosa, additional, Ruiz, Margarita Centelles, additional, Bridgewater, John, additional, Glynne-Jones, Rob, additional, Tahir, Saad, additional, Hickish, Tamas, additional, Cassidy, Jim, additional, and Samuel, Leslie, additional

Published
2017
Full Text
View/download PDF

14. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer

Author

Hendlisz, Alain, Deleporte, Amélie, Delaunoit, Thierry, Marechal, Raphaël, Peeters, Marc, Holbrechts, S., Van Den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Ceyssens, Sarah, Barbuto, Anna-Maria, Lhommel, Renaud, Demolin, Gauthier, Garcia, Camilo, El Mansy, Hazem, Ameye, Lieveke, Moreau, Michel, Guiot, Thomas, Paesmans, Marianne, Piccart-Gebhart, Martine, Flamen, Patrick, Santini, Daniele, UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Oncology, Sorafenib, Adult, Male, Niacinamide, medicine.medical_specialty, Pathology, Colorectal cancer, medicine.medical_treatment, Psychologie appliquée, lcsh:Medicine, Glucose-6-Phosphate, Disease-Free Survival, Capecitabine, Breast cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Prospective Studies, Neoplasm Metastasis, lcsh:Science, Aged, Aged, 80 and over, Chemotherapy, Multidisciplinary, business.industry, Phenylurea Compounds, lcsh:R, Sciences bio-médicales et agricoles, Middle Aged, medicine.disease, Radiography, Survival Rate, Positron-Emission Tomography, Toxicity, Biomarker (medicine), lcsh:Q, Female, business, Colorectal Neoplasms, Engineering sciences. Technology, Biologie, Drug metabolism, medicine.drug, Research Article
Abstract

Background Tumoral heterogeneity is a major determinant of resistance in solid tumors. FDG-PET/CT can identify early during chemotherapy non-responsive lesions within the whole body tumor load. This prospective multicentric proof-of-concept study explores intra-individual metabolic response (mR) heterogeneity as a treatment efficacy biomarker in chemorefractory metastatic colorectal cancer (mCRC). Methods Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m2/day administered D1-14 every 21 days). MR assessment was categorized according to the proportion of metabolically non-responding (non-mR) lesions (stable FDG uptake with SUV-max decrease, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2015

15. Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study [BMC Cancer, 13, (2013), 190]

Author

Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amélie, Mansy, Hazem El, Vandeputte, Caroline, Maetens, Marion M., Awada, Ahmad, Piccart-Gebhart, Martine, Paesmans, Marianne, Garcia, Camilo, Flamen, Patrick, Peeters, Michel, Annemans, Lieven, Van Den Eynde, Marc, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Marechal, Raphaël, and Van Laethem, Jean-Luc

Subjects
Cancérologie, Biologie
Abstract

SCOPUS: er.j, info:eu-repo/semantics/published

Published
2015

17. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer

Author

UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Hendlisz, Alain, Deleporte, Amelie, Delaunoit, Thierry, Maréchal, Raphaël, Peeters, Marc, Holbrechts, Stéphane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Ceyssens, Sarah, Barbuto, Anna-Maria, Lhommel, Renaud, Demolin, Gauthier, Garcia, Camilo, ElMansy, Hazem, Ameye, Lieveke, Moreau, Michel, Guiot, Thomas, Paesmans, Marianne, Piccart, Martine, Flamen, Patrick, Santini, Daniele, UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Hendlisz, Alain, Deleporte, Amelie, Delaunoit, Thierry, Maréchal, Raphaël, Peeters, Marc, Holbrechts, Stéphane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Ceyssens, Sarah, Barbuto, Anna-Maria, Lhommel, Renaud, Demolin, Gauthier, Garcia, Camilo, ElMansy, Hazem, Ameye, Lieveke, Moreau, Michel, Guiot, Thomas, Paesmans, Marianne, Piccart, Martine, Flamen, Patrick, and Santini, Daniele

Abstract

BACKGROUND: Tumoral heterogeneity is a major determinant of resistance in solid tumors. FDG-PET/CT can identify early during chemotherapy non-responsive lesions within the whole body tumor load. This prospective multicentric proof-of-concept study explores intra-individual metabolic response (mR) heterogeneity as a treatment efficacy biomarker in chemorefractory metastatic colorectal cancer (mCRC). METHODS: Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days). MR assessment was categorized according to the proportion of metabolically non-responding (non-mR) lesions (stable FDG uptake with SUVmax decrease <15%) among all measurable lesions. RESULTS: Ninety-two patients were included. The median overall survival (OS) and progression-free survival (PFS) were 8.2 months (95% CI: 6.8-10.5) and 4.2 months (95% CI: 3.4-4.8) respectively. In the 79 assessable patients, early PET-CT showed no metabolically refractory lesion in 47%, a heterogeneous mR with at least one non-mR lesion in 32%, and a consistent non-mR or early disease progression in 21%. On exploratory analysis, patients without any non-mR lesion showed a significantly longer PFS (HR 0.34; 95% CI: 0.21-0.56, P-value <0.001) and OS (HR 0.58; 95% CI: 0.36-0.92, P-value 0.02) compared to the other patients. The proportion of non-mR lesions within the tumor load did not impact PFS/OS. CONCLUSION: The presence of at least one metabolically refractory lesion is associated with a poorer outcome in advanced mCRC patients treated with combined sorafenib-capecitabine. Early detection of treatment-induced mR heterogeneity may represent an important predictive efficacy biomarker in mCRC. TRIAL REGISTRATION: ClinicalTrials.gov NCT01290926.

Published
2015

18. Erratum: Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amelie, Paesmans, Marianne, El Mansy, Hazem, Garcia, Camilo, Peeters, Marc, Annemans, Lieven, Vandeputte, Caroline, Maetens, Marion, Van den Eynde, Marc, Maréchal, Raphaël, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Awada, Ahmad, Piccart, Martine, Van Laethem, Jean-Luc, Flamen, Patrick, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amelie, Paesmans, Marianne, El Mansy, Hazem, Garcia, Camilo, Peeters, Marc, Annemans, Lieven, Vandeputte, Caroline, Maetens, Marion, Van den Eynde, Marc, Maréchal, Raphaël, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Awada, Ahmad, Piccart, Martine, Van Laethem, Jean-Luc, and Flamen, Patrick

Abstract

Erratum for Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. [BMC Cancer. 2013]

Published
2015

19. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Author

Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amelie, Paesmans, Marianne, El Mansy, Hazem, Garcia, Camilo, Peeters, Marc, Annemans, Lieven, Vandeputte, Caroline, Maetens, Marion, Van den Eynde, Marc, Maréchal, Raphaël, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Awada, Ahmad, Piccart, Martine, Van Laethem, Jean-Luc, Flamen, Patrick, Biomechanics and Human Biometry, Interuniversity Centre For Health Economics Research, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie

Subjects
Oncology, Cancer Research, Organoplatinum Compounds, Colorectal cancer, medicine.medical_treatment, Leucovorin, Polymorphism, Single Nucleotide -- genetics, Study Protocol, ESOPHAGOGASTRIC JUNCTION, FOLFOX, Belgium, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Medicine, PROGRESSION-FREE, Prospective Studies, Stage (cooking), FDG-PET, Adjuvant, Gene Rearrangement, Neoplastic Cells, Circulating, Prognosis, Adenocarcinoma -- drug therapy -- mortality -- pathology, RESPONSE EVALUATION, SOLID TUMORS, Colon cancer, Survival Rate, Chemotherapy, Adjuvant, Colonic Neoplasms, Neoplastic Cells, Circulating -- pathology, Colonic Neoplasms -- drug therapy -- mortality -- pathology, Organoplatinum Compounds -- therapeutic use, Fluorouracil, Erratum, Biologie, Early assessment, medicine.drug, medicine.medical_specialty, PET/CT, Adenocarcinoma, Polymorphism, Single Nucleotide, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Preoperative chemosensitivity testing as Predictor, Breast cancer, POSITRON-EMISSION-TOMOGRAPHY, LUNG-CANCER, Lymphocytes, Tumor-Infiltrating, Internal medicine, Preoperative Care, Genetics, BREAST-CANCER, Humans, Lung cancer, Chemosensitivity, RECTAL-CANCER, Neoplasm Staging, Chemotherapy, business.industry, Fluorouracil -- therapeutic use, medicine.disease, Leucovorin -- therapeutic use, CIRCULATING TUMOR-CELLS, Cancérologie, METASTATIC COLORECTAL-CANCER, Positron-Emission Tomography, Quality of Life, Human medicine, business, Tomography, X-Ray Computed, Chemosensitivity assay, Follow-Up Studies
Abstract

Background: Surgery is a curative treatment for patients with locally advanced colon cancer, but recurrences are frequent for those with stage III disease. FOLFOX adjuvant chemotherapy has been shown to improve recurrence-free survival and overall survival by more than 20% and is nowadays considered a standard of care. However, the vast majority of patients will not benefit from receiving cytotoxic drugs because they have either already been cured by surgery or because their tumor cells are resistant to the chemotherapy, for which predictive factors are still not available.Identifying which patients are unlikely to respond to adjuvant chemotherapy from among those who are eligible for such treatment would be a major step towards treatment personalization. It would spare such patients from unnecessary toxicities and would improve the allocation of societal healthcare resources.Methods/design: PePiTA is a prospective, multicenter, non-randomised trial built on the hypothesis that preoperative chemosensitivity testing using FDG-PET/CT before and after one course of FOLFOX can identify the patients who are unlikely to benefit from 6 months of adjuvant FOLFOX treatment for stage III colon cancer.The study's primary objective is to examine the ability of PET/CT-assessed tumor FDG uptake after one course of preoperative chemotherapy to predict the outcome of adjuvant therapy, as measured by 3-year disease-free survival.Secondary objectives are to examine the predictive value of changes in PET/CT-assessed tumor FDG uptake on overall survival, to define the best cut-off value of FDG uptake for predicting treatment outcome, and to analyse the cost-effectiveness of such preoperative chemo-sensitivity testing.At study planning, exploratory translational research objectives were 1) to assess the predictive value of circulating tumor cells for disease-free survival, 2) to examine the predictive value of single nucleotide polymorphisms for disease-free survival with respect to genes related either to toxicity or to drug targets, 3) to assess genomic rearrangements associated with response or resistance to FOLFOX treatment, 4) to identify an immunologic signature associated with metabolic tumor response to FOLFOX therapy and, finally, 5) to create a bank of frozen tumor samples for future studies.Discussion: PePiTA is the first study to use the primitive tumor chemosensitivity assessed by metabolic imaging as a guidance for adjuvant therapy in colon cancer. It could pave the way for tailoring the treatment and avoiding useless toxicities for the patients and inadequate expenses for the society. It could also give an interesting insight into tumoral heterogeneity, resistance to chemotherapy, genetic predisposants to oxaliplatin toxicity and immune response to cancer.EudraCT number: 2009-011445-13. Trial registration: ClinicalTrials.gov number, NCT00994864. © 2013 Hendlisz et al. licensee BioMed Central Ltd., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2013

20. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Author

Thaler, Josef, primary, Greil, Richard, additional, Gaenzer, Johannes, additional, Eisterer, Wolfgang, additional, Tschmelitsch, Joerg, additional, Samonigg, Hellmut, additional, Zabernigg, August, additional, Schmid, Franz, additional, Steger, Günther, additional, Steinacher, Robert, additional, Andel, Johannes, additional, Lang, Alois, additional, Függer, Reinhold, additional, Hofbauer, Friedrich, additional, Woell, Ewald, additional, Geissler, Dietmar, additional, Lenauer, Alfred, additional, Prager, Manfred, additional, Van Laethem, Jean-Luc, additional, Van Cutsem, Eric, additional, D'Haens, Geert, additional, Demolin, Gauthier, additional, Kerger, Joseph, additional, Deboever, Guido, additional, Ghillebert, Gilbert, additional, Polus, Marc, additional, RezaieKalantari, Hassan, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles, additional, Peeters, Marc, additional, Vergauwe, Philippe, additional, Houbiers, Ghislain, additional, Humblet, Yves, additional, Janssens, Jos, additional, Schrijvers, Dirk, additional, Vanderstraeten, Erik, additional, Vermorken, Jan, additional, Van Daele, Daniel, additional, Ferrante, Michel, additional, Forget, Frederic, additional, Hendlisz, Alain, additional, Yilmaz, Mette, additional, Nielsen, Svend Erik, additional, Vestermark, Lene, additional, Larsen, Jim, additional, Ychou, Marc, additional, Zawadi, Ayman, additional, Zawadi, Mohamed-Ayman, additional, Bouche, Olivier, additional, Mineur, Laurent, additional, Bennouna-Louridi, Jaafar, additional, Dourthe, Louis Marie, additional, Boucher, Eveline, additional, Taieb, Julien, additional, Pezet, Denis, additional, Desseigne, Francoise, additional, Ducreux, Michel, additional, Texereau, Patrick, additional, Miglianico, Laurent, additional, Rougier, Philippe, additional, Fratte, Serge, additional, Levache, Charles-Briac, additional, Merrouche,, Yacine, additional, Ellis, Stephen, additional, Locher, Christophe, additional, Ramee, Jean-Francois, additional, Garnier, Claire, additional, Viret, Frederic, additional, Chauffert, Bruno, additional, Cojean-Zelek, Isabelle, additional, Michel, Pierre, additional, Lecaille, Cedric, additional, Borel, Christian, additional, Seitz, Jean-Francois, additional, Smith, Denis, additional, Lombard-Bohas, Catherine, additional, Andre, Thierry, additional, Gornet, Jean-Marc, additional, Fein, Francine, additional, Coulon-Sfairi, Marie-Aude, additional, Kaminsky, Marie-Christine, additional, Lagasse, Jean-Paul, additional, Luet, Dominique, additional, Etienne, Pierre-Luc, additional, Gasmi, Mohamed, additional, Vanoli, Andre, additional, Nguyen, Suzanne, additional, Aparicio, Thomas, additional, Perrier, Hervé, additional, Stremsdoerfer, Noel, additional, Laplaige, Philippe, additional, Arsene, Dominique, additional, Auby, Dominique, additional, Bedenne, Laurent, additional, Coriat, Romain, additional, Denis, Bernard, additional, Geoffroy, Patrick, additional, Piot, Gilles, additional, Becouarn, Yves, additional, Bordes, Gilbert, additional, Deplanque, Gael, additional, Dupuis, Olivier, additional, Fruge, Frederic, additional, Guimbaud, Rosine, additional, Lecomte, Thierry, additional, Lledo, Gérard, additional, Sobhani, Iradej, additional, Asnacios, Amani, additional, Azzedine, Ahmed, additional, Desauw, Christophe, additional, Galais, Marie-Pierre, additional, Gargot, Dany, additional, Lam, You-Heng, additional, Abakar-Mahamat, Abakar, additional, Berdah, Jean-Francois, additional, Catteau, Sylviane, additional, Clavero-Fabri, Marie-Christine, additional, Codoul, Jean-Francois, additional, Legoux, Jean-Louis, additional, Goldfain, Denis, additional, Guichard, Pierre, additional, Verge, Denis Pere, additional, Provencal, Jocelyne, additional, Vedrenne, Bruno, additional, Brezault-Bonnet, Catherine, additional, Cleau, Denis, additional, Desir, Jean-Paul, additional, Fallik, David, additional, Garcia, Bruno, additional, Gaspard, Marie-Hélène, additional, Genet, Dominique, additional, Hartwig, Johannes, additional, Krummel, Yves, additional, MatysiakBudnik, Tamara, additional, Palascak-Juif, Vanessa, additional, Randrianarivelo, Harizo, additional, Rinaldi, Yves, additional, Aleba, Albert, additional, Darut-Jouve, Ariane, additional, de Gramont, Aimery, additional, Hamon, Herve, additional, Wendehenne, Frederic, additional, Matzdorff, Axel, additional, Stahl, Michael Konrad, additional, Schepp, Wolfgang, additional, Burk, Martin, additional, Mueller, Lothar, additional, Folprecht, Gunnar, additional, Geissler, Michael, additional, Mantovani-Loeffler, Luisa, additional, Hoehler, Thomas, additional, Asperger, Walter, additional, Kroening, Hendrik, additional, von Weikersthal, Ludwig Fischer, additional, Fuxius, Stefan, additional, Groschek, Matthias, additional, Meiler, Johannes, additional, Trarbach, Tanja, additional, Rauh, Jacqueline, additional, Ziegenhagen, Nicolas, additional, Kretzschmar, Albrecht, additional, Graeven, Ullrich, additional, Nusch, Arnd, additional, von Wichert, Goetz, additional, Hofheinz, Ralf-Dieter, additional, Kleber, Gerhard, additional, Schmidt, Karl-Heinz, additional, Vehling-Kaiser, Ursula, additional, Baum, Claudia, additional, Schuette, Jochen, additional, Haag, Georg Martin, additional, Holtkamp, Wilhelm, additional, Potenberg, Jochen, additional, Reiber, Tobias, additional, Schliesser, Georg, additional, Schmoll, Hans-Joachim, additional, Schneider-Kappus, Wolfgang, additional, Abenhardt, Wolfgang, additional, Denzlinger, Claudio, additional, Henning, Jan, additional, Marxsen, Bartscht, additional, GuenterDerigs, Hans, additional, Lambertz, Helmut, additional, Becker-Boost, Ingulf, additional, Caca, Karel, additional, Constantin, Christian, additional, Decker, Thomas, additional, Eschenburg, Henning, additional, Gabius, Sigrun, additional, Hebart, Holger, additional, Hoffmeister, Albrecht, additional, Horst, Heinz-August, additional, Kremers, Stephan, additional, Leithaeuser, Malte, additional, Mueller, Sebastian, additional, Wagner, Siegfried, additional, Daum, Severin, additional, Schlegel, Frank, additional, Stauch, Martina, additional, Heinemann, Volker, additional, Labianca, Roberto, additional, Colucci, Giuseppe, additional, Amadori, Dino, additional, Mini, Enrico, additional, Falcone, Alfredo, additional, Boni, Corrado, additional, Maiello, Evaristo, additional, Latini, Luciano, additional, Zaniboni, Alberto, additional, Aprile, Giuseppe, additional, Barni, Sandro, additional, Mattioli, Rodolfo, additional, Martoni, Andrea, additional, Passalacqua, Rodolfo, additional, Nicolini, Mario, additional, Pasquini, Enzo, additional, Rabbi, Carla, additional, Aitini, Enrico, additional, Ravaioli, Alberto, additional, Barone, Carlo, additional, Biasco, Guido, additional, Tamberi, Stefano, additional, Gambi, Angelo, additional, Verusio, Claudio, additional, Marzola, Marina, additional, Lelli, Giorgio, additional, Cascinu, Stefano, additional, Bidoli, Paolo, additional, Vaghi, Massimo, additional, Cruciani, Giorgio, additional, Di Costanzo, Francesco, additional, Sobrero, Alberto, additional, Petrioli, Roberto, additional, Aglietta, Massimo, additional, Alabiso, Oscar, additional, Capuzzo, Federico, additional, Corsi, Domenico Cristi, additional, Salvagni, Stefania, additional, Chiara, Silvana, additional, Ferraù, Francesco, additional, Giuliani, Francesco, additional, Lonardi, Sara, additional, Gebbia, Nicola, additional, Mantovani, Giovanni, additional, Sanches, Evaristo, additional, Mellidez, Juan Carlos, additional, Santos, Pedro, additional, Freire, Joao, additional, Sarmento, Cristina, additional, Costa, Luis, additional, Pinto, Antonio Moreira, additional, Barroso, Sergio, additional, Santo, Jorge Espirito, additional, Guedes, Fátima, additional, Monteiro, Amélia, additional, Sa, Anabela, additional, Furtado, Irene, additional, Tabernero, Josep, additional, Salazar, Ramon, additional, Aguilar, Enrique Aranda, additional, Herrero, Fernando Rivera, additional, Valera, Javier Sastre, additional, ValladaresAyerbes, Manuel, additional, FeliuBatlle, Jaime, additional, Gil, Silvia, additional, Garcia-Giron, Carlos, additional, Vivanco, Guillermo Lopez, additional, Salvia, Antonia Salud, additional, Orduña, Vicente Alonso, additional, Garcia, Ruth Vera, additional, Gallego, Javier, additional, Sureda, Bartomeu Massuti, additional, Remon, Jordi, additional, Safont Aguilera, Maria Jose, additional, CireraNogueras, Luis, additional, Merino, BernadoQueralt, additional, Castro, Cristina Gravalos, additional, de Prado, Purificacion Martinez, additional, PijaumePericay, Carlos, additional, ConstenlaFigueiras, Manuel, additional, Jordan, InmaculadaGuasch, additional, GomeReina, Maria Jose, additional, Garcia, Amelia Lopez-Ladron, additional, Garcia-Ramos, Antonio Arrivi, additional, Cervantes, Andres, additional, Martos, Carlos Fernandez, additional, MarcuelloGaspar, Eugenio, additional, Montero, Ines Cabezas, additional, Emperador, Pilar Escudero, additional, Carbonero, Ana Leon, additional, Castillo, Manuel Gallen, additional, Garcia, Teresa Garcia, additional, Lopez, Jose Garcia, additional, Flores, Encarnacion Gonzalez, additional, GuillotMorales, Monica, additional, LlanosMuñoz, Marta, additional, Martín, Ana López, additional, Maurel, Joan, additional, Camara, Juan Carlos, additional, Garcia, Rosario Dueñas, additional, Salgado, Mercedes, additional, HernandezBusquier, Isabel, additional, Ruiz, Teresa Checa, additional, LacastaMuñoa, Adelaida, additional, Aliguer, MiquelNogue, additional, Ortiz de Taranco, Amalia Velasco, additional, Ureña, Miguel Mendez, additional, Gaspa, Ferran Losa, additional, Ponce, Jose Juan, additional, Roig, Carlos Bosch, additional, Jimenez, Pedro Valero, additional, GalanBrotons, Antonio, additional, AlbiolRodriguez, Santiago, additional, Martinez, Jose Ales, additional, Ruiz, Liliana Canosa, additional, CentellesRuiz, Margarita, additional, Bridgewater, John, additional, Glynne-Jones, Rob, additional, Tahir, Saad, additional, Hickish, Tamas, additional, Cassidy, Jim, additional, and Samuel, Leslie, additional

Published
2015
Full Text
View/download PDF

21. Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Author

Hendlisz, Alain, primary, Golfinopoulos, Vassilis, additional, Deleporte, Amelie, additional, Paesmans, Marianne, additional, El Mansy, Hazem, additional, Garcia, Camilo, additional, Peeters, Marc, additional, Annemans, Lieven, additional, Vandeputte, Caroline, additional, Maetens, Marion, additional, Van den Eynde, Marc, additional, Maréchal, Raphaël, additional, Borbath, Ivan, additional, Dresse, Damien, additional, Houbiers, Ghislain, additional, Fried, Michael, additional, Awada, Ahmad, additional, Piccart, Martine, additional, Van Laethem, Jean-Luc, additional, and Flamen, Patrick, additional

Published
2015
Full Text
View/download PDF

22. Randomized phase II studies comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab or cetuximab with FOLFOX or FOLFIRI.

Author

Van Den Eynde, Marc, primary, Castella, Marie-Laure, additional, Machiels, Jean-Pascal H., additional, Humblet, Yves, additional, Canon, Jean-Luc Re, additional, Houbiers, Ghislain, additional, Demolin, Gauthier, additional, D'Hondt, Lionel A., additional, Coche, Jean-Charles, additional, Van Daele, Daniel, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles., additional, Beniuga, Gabriella, additional, Pairet, Geraldine, additional, Sempoux, Christine, additional, Jouret-Mourin, Anne, additional, Van Maanen, Aline, additional, and Carrasco, Javier, additional

Published
2015
Full Text
View/download PDF

23. SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Centre du cancer, Deleporte, Amélie, Hendlisz, Alain, Garcia, Camilo, Delaunoit, Thierry, Maréchal, Raphael, Peeters, Marc, Holbrechts, Stephane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Rolfo, Christian Diego, Diaz, Marie, Lhommel, Renaud, Demolin, Gauthier, Moreau, Michel, Ameye, Lieveke, Paesmans, Marianne, Piccart-Gebhart, Martine J., Flamen, Patrick, 2014 ASCO GI Annual Meeting, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Centre du cancer, Deleporte, Amélie, Hendlisz, Alain, Garcia, Camilo, Delaunoit, Thierry, Maréchal, Raphael, Peeters, Marc, Holbrechts, Stephane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Rolfo, Christian Diego, Diaz, Marie, Lhommel, Renaud, Demolin, Gauthier, Moreau, Michel, Ameye, Lieveke, Paesmans, Marianne, Piccart-Gebhart, Martine J., Flamen, Patrick, and 2014 ASCO GI Annual Meeting

Abstract

Background: The SOR-CAP combination has shown clinical activity in several phase I-II trials involving metastatic breast cancer and mCRC patients (pts). SoMore aims to substantiate the combination’s effects in mCRC refractory to all medications and the predictive value of early metabolic response (MR) on survival. Methods: SoMore (EUDRACT 2010-023695-91) has 2 coprimary objectives: 1) to demonstrate an overall survival (OS) rate at 6 months (mths) > 30%, and 2) to compare OS between pts with and without MR. CAP was given at 1700 mg/m²/day (D), 2 weeks out of 3. SOR was administered at 600mg/D for the first cycle, then at 800mg/D until progression or unacceptable toxicity. FDGPET-CT was performed at baseline and before the 2nd cycle. MR analysis was centralized and blinded for the investigators. Results: From February to October 2011, 92 eligible pts were prospectively recruited in 6 Belgian centers: M/F: 54%/46%; ECOG PS 0/1: 55%/45%; median age: 61. A median of 5 treatment cycles were given (0-28+). Grade 3-4 toxic reactions were reported in 61.2%, mainly fatigue (18%), hand-foot skin reaction (14%) and diarrhea (11%), but no toxic death. 6.9% of the pts stopped therapy due to toxicity. 6 mths OS was 71% (95% CI: 61%-79%), significantly >30% (p<0.001). 47% of the 79 pts evaluable for metabolic assessment showed homogeneous MR (HMR) of all metastatic lesions, 32% mixed MR and 21% homogeneous non-MR. Median overall OS and PFS of the intent-to-treat population and of pts with and without HMR are shown in the table below. Hazard ratio for HMR was 0.34 (95% CI, 0.21 to 0.56) p-value <0.001 for PFS and 0.59 (95% CI, 0.37 to 0.96) p-value 0.03 for OS. Conclusions: These data suggest robust efficacy for the SOR-CAP combination in heavily pretreated mCRC, associated with high but manageable toxicity. Early MR assessment, by detecting unresponsive lesions within the whole body tumoral load, is able to capture the pts’ likelihood of benefit, opening the path to personalized m

Published
2014

24. SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).

Author

Deleporte, Amélie, primary, Hendlisz, Alain, additional, Garcia, Camilo, additional, Delaunoit, Thierry, additional, Maréchal, Raphael, additional, Peeters, Marc, additional, Holbrechts, Stephane, additional, Van Den Eynde, Marc, additional, Houbiers, Ghislain, additional, Filleul, Bertrand, additional, Van Laethem, Jean-Luc, additional, Rolfo, Christian Diego, additional, Diaz, Marie, additional, Lhommel, Renaud, additional, Demolin, Gauthier, additional, Moreau, Michel, additional, Ameye, Lieveke, additional, Paesmans, Marianne, additional, Piccart-Gebhart, Martine J., additional, and Flamen, Patrick, additional

Published
2014
Full Text
View/download PDF

25. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amelie, Paesmans, Marianne, Mansy, Hazem El, Garcia, Camilo, Peeters, Marc, Annemans, Lieven, Vandeputte, Caroline, Maetens, Marion, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Awada, Ahmad, Piccart, Martine, Laethem, Jean-Luc Van, Flamen, Patrick, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Hendlisz, Alain, Golfinopoulos, Vassilis, Deleporte, Amelie, Paesmans, Marianne, Mansy, Hazem El, Garcia, Camilo, Peeters, Marc, Annemans, Lieven, Vandeputte, Caroline, Maetens, Marion, Borbath, Ivan, Dresse, Damien, Houbiers, Ghislain, Fried, Michael, Awada, Ahmad, Piccart, Martine, Laethem, Jean-Luc Van, and Flamen, Patrick

Published
2013

26. SoMore trial:Prospective multicentric clinical and metabolic assessment of a sorafenib(SOR)-capecitabine(CAP)combination in patients with chemorefractory advanced colorectal cancer(aCRC)

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de médecine nucléaire, Deleporte, Amélie, Hendlisz, Alain, Garcia, Camilo, Delaunoit, Thierry, Maréchal, Raphaël, Peeters, Marc, Holbrechts, Stéphane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean Luc, Ceyssens, Sarah, Barbuto, Anna Maria, Lhommel, Renaud, Demolin, Gauthier, Moreau, Michel, Paesmans, Marianne, Piccart, Martine, Flamen, Patrick, ASCO Annual Meeting, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de médecine nucléaire, Deleporte, Amélie, Hendlisz, Alain, Garcia, Camilo, Delaunoit, Thierry, Maréchal, Raphaël, Peeters, Marc, Holbrechts, Stéphane, Van den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean Luc, Ceyssens, Sarah, Barbuto, Anna Maria, Lhommel, Renaud, Demolin, Gauthier, Moreau, Michel, Paesmans, Marianne, Piccart, Martine, Flamen, Patrick, and ASCO Annual Meeting

Abstract

n/a

Published
2012

27. SOMORE trial: combining sorafenib with capecitabine yields highly encouraging survival results and elevated metabolic response rate in chemorefractory metastatic colorectal cancer

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Deleporte, Amélie, Hendlisz, Alain, Delaunoit, Thierry, Maréchal, Raphael, Peeters, Marc, Holbrecht, Stephane, Van den Eynde, Marc, Houbiers, Ghislain, Moreau, Michel, Flamen, Patrick, ESMO 2012 Congress, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Deleporte, Amélie, Hendlisz, Alain, Delaunoit, Thierry, Maréchal, Raphael, Peeters, Marc, Holbrecht, Stephane, Van den Eynde, Marc, Houbiers, Ghislain, Moreau, Michel, Flamen, Patrick, and ESMO 2012 Congress

Published
2012

28. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.

Author

Verset, Gontran, Verslype, Chris, Reynaert, Herwig, Borbath, Ivan, Langlet, Philippe, Vandebroek, A, Peeters, Michel, Houbiers, Ghislain, Francque, S, Arvanitakis, Marianna, Van Laethem, Jean-Luc, Verset, Gontran, Verslype, Chris, Reynaert, Herwig, Borbath, Ivan, Langlet, Philippe, Vandebroek, A, Peeters, Michel, Houbiers, Ghislain, Francque, S, Arvanitakis, Marianna, and Van Laethem, Jean-Luc

Abstract

To assess the efficacy of the combination of long-acting release (LAR) octreotide and tamoxifen (TMX) for the treatment of advanced hepatocellular carcinoma (HCC). A total of 109 patients with advanced HCC were randomised to receive octreotide LAR combined with TMX (n=56) (experimental treatment group) or TMX alone (n=53; control group). The clinical, biological and tumoural parameters were recorded every 3 months until death. Primary end point was patient survival; secondary end points were the impact of therapy on tumour response, quality of life and variceal bleeding episodes. Univariate and multivariate analyses were performed for assessment of specific prognostic factors. The median survival was 3 months (95% CI 1.4-4.6) for the experimental treatment group and 6 months (CI 95% 2-10) for the control group (P=0.609). There was no difference in terms of alpha-foetoprotein (alpha-FP) decrease, tumour regression, improvement of quality of life and prevention of variceal bleeding between the two groups. Variables associated with a better survival in the multivariate analysis were: presence of cirrhosis, alpha-FP level <400 ng ml(-1) and Okuda stage I. The combination of octreotide LAR and TMX does not influence survival, tumour progression or quality of life in patients with advanced HCC., Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2007

29. Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

Author

Van Laethem, Jean-Luc, Van Maele, Ph, Verslype, Chris, Polus, Marc, Demols, Anne, Houbiers, Ghislain, Caenepeel, P., Leleux, A., Vermaut, R R, Van Cutsem, Eric, Peeters, Marc, Van Laethem, Jean-Luc, Van Maele, Ph, Verslype, Chris, Polus, Marc, Demols, Anne, Houbiers, Ghislain, Caenepeel, P., Leleux, A., Vermaut, R R, Van Cutsem, Eric, and Peeters, Marc

Abstract

This multicenter phase II study was designed to determine the activity and tolerance of gemcitabine and raltitrexed in advanced pancreatic adenocarcinoma., Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2004

31. Acute pancreatitis attributed to the use of interferon alfa-2b

Author

Eland, Ingo A., primary, Rasch, Marijke C., additional, Sturkenboom, Miriam J.C.M., additional, Bekkering, Frank C., additional, Brouwer, Johannes T., additional, Delwaide, Jean, additional, Belaiche, Jacques, additional, Houbiers, Ghislain, additional, and Stricker, Bruno H.Ch., additional

Published
2000
Full Text
View/download PDF

32. Dietetic and Psychological Mindfulness Workshops for the Management of Cachectic Cancer Patients. A Randomized Study.

Author

Focan C, Houbiers G, Gilles L, Van Steeland T, Georges N, Maniglia A, Lobelle JP, Baro V, and Graas MP

Subjects
Adult, Aged, Cachexia etiology, Case-Control Studies, Disease Management, Emotions, Fatigue etiology, Fatigue prevention & control, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms pathology, Prognosis, Stress, Psychological prevention & control, Surveys and Questionnaires, Adaptation, Psychological, Cachexia prevention & control, Cachexia psychology, Dietetics, Mindfulness, Neoplasms complications, Quality of Life
Abstract

Aim: To determine if actively-treated cancer patients developing cachexia could benefit from participation to mindfulness workshops., Patients and Methods: Subjects developing cachexia signs while treated for cancer were randomized in a trial aiming to compare an experimental group that would participate to specific workshops based on mindfulness alternating dietetic and psychological approaches, and a control group managed in accordance to usual practice., Results: The recruitment was difficult (12% of the approached population). Finally 53 patients accepted to participate. Despite an unpredictable compliance of workshop participants, the final satisfaction score attained 75%. In comparison with the control group, patients randomized to the experimental group showed a significant benefit with an increase of their body weight and an improvement of their WHO status score. They also experienced an improvement of emotional function and observation faculty as well as a relief of fatigue and some digestive disorders., Conclusion: Selected cachectic cancer patients may benefit from this experimental approach. This approach may, however, be difficult to implement on a large scale., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results